Ansal Buildwell Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 29, 2025, 7:41 pm

Quick Insight

Ansal Buildwell Ltd, operating in the Construction, Contracting & Engineering sector, currently shows a price of 117 with a market cap of 86.1 Cr. The company's P/E stands at 58.6, indicating a relatively high valuation compared to its earnings. With an ROE of 6.31% and ROCE of 9.85%, Ansal Buildwell's profitability metrics suggest room for improvement. The OPM at 27.30% is decent, but the low P/BV ratio of 0.58x raises concerns about the stock's underlying value. Additionally, the high CCC of 9,196.89 days and a moderate ICR of 3.97x warrant a closer look at the company's operational efficiency and debt management. Investors should carefully evaluate these factors before making any investment decisions.

Competitors of Ansal Buildwell Ltd

All Competitor Stocks of Ansal Buildwell Ltd

Quarterly Result

Last Updated: August 19, 2025, 11:40 pm

Below is a detailed analysis of the quarterly data for Ansal Buildwell Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 9.78 Cr.. The value appears to be declining and may need further review. It has decreased from 15.22 Cr. (Mar 2025) to 9.78 Cr., marking a decrease of 5.44 Cr..
• For Expenses, as of Jun 2025, the value is 7.11 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 10.19 Cr. (Mar 2025) to 7.11 Cr., marking a decrease of 3.08 Cr..
• For Operating Profit, as of Jun 2025, the value is 2.67 Cr.. The value appears to be declining and may need further review. It has decreased from 5.03 Cr. (Mar 2025) to 2.67 Cr., marking a decrease of 2.36 Cr..
• For OPM %, as of Jun 2025, the value is 27.30%. The value appears to be declining and may need further review. It has decreased from 33.05% (Mar 2025) to 27.30%, marking a decrease of 5.75%.
• For Other Income, as of Jun 2025, the value is 0.84 Cr.. The value appears to be declining and may need further review. It has decreased from 1.74 Cr. (Mar 2025) to 0.84 Cr., marking a decrease of 0.90 Cr..
• For Interest, as of Jun 2025, the value is 1.20 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.42 Cr. (Mar 2025) to 1.20 Cr., marking a decrease of 0.22 Cr..
• For Depreciation, as of Jun 2025, the value is 0.59 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.57 Cr. (Mar 2025) to 0.59 Cr., marking an increase of 0.02 Cr..
• For Profit before tax, as of Jun 2025, the value is 1.72 Cr.. The value appears to be declining and may need further review. It has decreased from 4.78 Cr. (Mar 2025) to 1.72 Cr., marking a decrease of 3.06 Cr..
• For Tax %, as of Jun 2025, the value is 28.49%. The value appears to be improving (decreasing) as expected. It has decreased from 90.38% (Mar 2025) to 28.49%, marking a decrease of 61.89%.
• For Net Profit, as of Jun 2025, the value is 1.29 Cr.. The value appears to be declining and may need further review. It has decreased from 4.53 Cr. (Mar 2025) to 1.29 Cr., marking a decrease of 3.24 Cr..
• For EPS in Rs, as of Jun 2025, the value is 1.75. The value appears to be declining and may need further review. It has decreased from 6.14 (Mar 2025) to 1.75, marking a decrease of 4.39.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: August 22, 2025, 7:34 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 1:53 pm

Below is a detailed analysis of the balance sheet data for Ansal Buildwell Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 7.38 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 7.38 Cr..
• For Reserves, as of Mar 2025, the value is 122.29 Cr.. The value appears strong and on an upward trend. It has increased from 115.27 Cr. (Mar 2024) to 122.29 Cr., marking an increase of 7.02 Cr..
• For Borrowings, as of Mar 2025, the value is 42.05 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 31.97 Cr. (Mar 2024) to 42.05 Cr., marking an increase of 10.08 Cr..
• For Other Liabilities, as of Mar 2025, the value is 362.34 Cr.. The value appears to be improving (decreasing). It has decreased from 363.31 Cr. (Mar 2024) to 362.34 Cr., marking a decrease of 0.97 Cr..
• For Total Liabilities, as of Mar 2025, the value is 534.06 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 517.93 Cr. (Mar 2024) to 534.06 Cr., marking an increase of 16.13 Cr..
• For Fixed Assets, as of Mar 2025, the value is 6.97 Cr.. The value appears strong and on an upward trend. It has increased from 3.30 Cr. (Mar 2024) to 6.97 Cr., marking an increase of 3.67 Cr..
• For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Investments, as of Mar 2025, the value is 48.15 Cr.. The value appears strong and on an upward trend. It has increased from 45.65 Cr. (Mar 2024) to 48.15 Cr., marking an increase of 2.50 Cr..
• For Other Assets, as of Mar 2025, the value is 478.94 Cr.. The value appears strong and on an upward trend. It has increased from 468.98 Cr. (Mar 2024) to 478.94 Cr., marking an increase of 9.96 Cr..
• For Total Assets, as of Mar 2025, the value is 534.06 Cr.. The value appears strong and on an upward trend. It has increased from 517.93 Cr. (Mar 2024) to 534.06 Cr., marking an increase of 16.13 Cr..

Notably, the Reserves (122.29 Cr.) exceed the Borrowings (42.05 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Key Financial Ratios

After reviewing the key financial ratios for Ansal Buildwell Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 10.78. This value is within the healthy range. It has decreased from 19.65 (Mar 24) to 10.78, marking a decrease of 8.87.
• For Diluted EPS (Rs.), as of Mar 25, the value is 10.78. This value is within the healthy range. It has decreased from 19.65 (Mar 24) to 10.78, marking a decrease of 8.87.
• For Cash EPS (Rs.), as of Mar 25, the value is 10.27. This value is within the healthy range. It has decreased from 15.91 (Mar 24) to 10.27, marking a decrease of 5.64.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 175.62. It has increased from 166.11 (Mar 24) to 175.62, marking an increase of 9.51.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 175.62. It has increased from 166.11 (Mar 24) to 175.62, marking an increase of 9.51.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 66.20. It has increased from 56.02 (Mar 24) to 66.20, marking an increase of 10.18.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 24.68. This value is within the healthy range. It has decreased from 29.07 (Mar 24) to 24.68, marking a decrease of 4.39.
• For PBIT / Share (Rs.), as of Mar 25, the value is 21.78. This value is within the healthy range. It has decreased from 26.20 (Mar 24) to 21.78, marking a decrease of 4.42.
• For PBT / Share (Rs.), as of Mar 25, the value is 15.57. This value is within the healthy range. It has decreased from 20.68 (Mar 24) to 15.57, marking a decrease of 5.11.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 7.36. This value is within the healthy range. It has decreased from 13.04 (Mar 24) to 7.36, marking a decrease of 5.68.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 10.78. This value is within the healthy range. It has decreased from 19.65 (Mar 24) to 10.78, marking a decrease of 8.87.
• For PBDIT Margin (%), as of Mar 25, the value is 37.28. This value is within the healthy range. It has decreased from 51.88 (Mar 24) to 37.28, marking a decrease of 14.60.
• For PBIT Margin (%), as of Mar 25, the value is 32.89. This value exceeds the healthy maximum of 20. It has decreased from 46.76 (Mar 24) to 32.89, marking a decrease of 13.87.
• For PBT Margin (%), as of Mar 25, the value is 23.51. This value is within the healthy range. It has decreased from 36.91 (Mar 24) to 23.51, marking a decrease of 13.40.
• For Net Profit Margin (%), as of Mar 25, the value is 11.12. This value exceeds the healthy maximum of 10. It has decreased from 23.27 (Mar 24) to 11.12, marking a decrease of 12.15.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 16.28. This value is within the healthy range. It has decreased from 35.06 (Mar 24) to 16.28, marking a decrease of 18.78.
• For Return on Networth / Equity (%), as of Mar 25, the value is 6.13. This value is below the healthy minimum of 15. It has decreased from 11.82 (Mar 24) to 6.13, marking a decrease of 5.69.
• For Return on Capital Employeed (%), as of Mar 25, the value is 9.68. This value is below the healthy minimum of 10. It has decreased from 12.54 (Mar 24) to 9.68, marking a decrease of 2.86.
• For Return On Assets (%), as of Mar 25, the value is 1.49. This value is below the healthy minimum of 5. It has decreased from 2.80 (Mar 24) to 1.49, marking a decrease of 1.31.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.07. This value is below the healthy minimum of 0.2. It has increased from 0.06 (Mar 24) to 0.07, marking an increase of 0.01.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.29. This value is within the healthy range. It has increased from 0.25 (Mar 24) to 0.29, marking an increase of 0.04.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.09. It has increased from 0.08 (Mar 24) to 0.09, marking an increase of 0.01.
• For Current Ratio (X), as of Mar 25, the value is 1.27. This value is below the healthy minimum of 1.5. It has increased from 1.26 (Mar 24) to 1.27, marking an increase of 0.01.
• For Quick Ratio (X), as of Mar 25, the value is 0.23. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.23.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.03. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 24) to 0.03, marking an increase of 0.03.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 3.97. This value is within the healthy range. It has decreased from 5.27 (Mar 24) to 3.97, marking a decrease of 1.30.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.19. This value is below the healthy minimum of 3. It has decreased from 3.36 (Mar 24) to 2.19, marking a decrease of 1.17.
• For Enterprise Value (Cr.), as of Mar 25, the value is 91.96. It has decreased from 112.87 (Mar 24) to 91.96, marking a decrease of 20.91.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.88. This value is within the healthy range. It has decreased from 2.73 (Mar 24) to 1.88, marking a decrease of 0.85.
• For EV / EBITDA (X), as of Mar 25, the value is 5.05. This value is within the healthy range. It has decreased from 5.26 (Mar 24) to 5.05, marking a decrease of 0.21.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.55. This value is within the healthy range. It has decreased from 2.59 (Mar 24) to 1.55, marking a decrease of 1.04.
• For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Price / BV (X), as of Mar 25, the value is 0.58. This value is below the healthy minimum of 1. It has decreased from 0.87 (Mar 24) to 0.58, marking a decrease of 0.29.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.55. This value is within the healthy range. It has decreased from 2.59 (Mar 24) to 1.55, marking a decrease of 1.04.
• For EarningsYield, as of Mar 25, the value is 0.10. This value is below the healthy minimum of 5. It has decreased from 0.13 (Mar 24) to 0.10, marking a decrease of 0.03.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness